Used to monitor Asparaginase therapy for sufficient enzyme activity, to assess silent inactivation by patient sensitization (activity assay). To assess if a patient is producing antibodies against asparaginase (antibody assay).

Measurement of samples are made against a standard curve generated from E. coli L‐asparaginase with each run. Calculations for Erwinaze®, Oncaspar®, Asparlas, and Rylaze® were empirically derived and utilize a correction factor that has been correlated to the E. coli L‐asparaginase activity.

Red serum vial/tube, 5 mL

Immediately following collection, mix sample by gently inverting 5 times

1. Allow sample to clot for a minimum of 30 minutes
2. Spin within two (2) hours of sample collection
3. Transfer serum to a False bottom plasma/serum transport vial/tube (AHL), labelled as serum

False bottom plasma/serum transport vial/tube (AHL)

Gold serum separator (SST) tube

Immediately following collection, mix sample by gently inverting 5 times

1. Allow sample to clot for a minimum of 30 minutes
2. Spin within two (2) hours of sample collection
3. Transfer serum to a false bottom plasma/serum transport vial/tube (AHL), labelled as serum

False bottom plasma/serum transport vial/tube (AHL)

Indicate date and time of last injection on Granger Genetics Requistion

Frozen (preferred) - 30 days

Refrigerated - 3 days

Ambient - 1 day

Freeze/Thaw Cycles: 3

Gross hemolysis, lipemia or icterus

Spectrophotometry/absorbance-based enzyme‐coupled kinetic reaction

Traditional antigen-capture ELISA assay

None. Physician established therapeutic range.

• 82657 x 4 (If the drug administered is not specified then results will be reported for Oncaspar, Erwinaze, Asparlas, and Rylaze)